ChemBioChemBiochemistryPeer-reviewed journal article
Development of a genetically encoded and potent PDE6D inhibitor
Atanasio Gómez‐MulasiD, Elisabeth Schaffner‐ReckingeriD, Hanne PeetersiD, Rohan ChippalkattiiD, Arnela DautbasiciD, Matthew James SmithiD, Shehab IsmailiD, Daniel AbankwaiD
Abstract
PDE6D is a trafficking chaperone of prenylated proteins, such as small GTPases. Several small molecule inhibitors have been developed against it, given that the oncogene K-Ras is one of the cargo proteins. Inhibitor development suffered from the fact that inhibitors against the hydrophobic pocket of PDE6D were typically poorly water-soluble. Here we describe the development of genetically encoded inhibitors that are inspired by high-affinity natural cargo of PDE6D. Our most potent inhibitor, SNAP-STI, encodes merely a farnesylated tetra-peptide, which efficiently blocks PDE6D binding of farnesylated cargo. Direct comparison with small molecule PDE6D inhibitors suggests its higher potency. We show that inhibition of K-Ras membrane anchorage and K-RasG12C-dependent MAPK-signaling by SNAP-STI is weak, consistent with what is observed after PDE6D knockdown. Our data therefore further support that PDE6D is not a suitable surrogate target for efficient inhibition of K-Ras membrane anchorage and MAPK-activity. Nonetheless, by exploiting contacts at the pocket entry, we established a generalizable strategy to design high-affinity PDE6D inhibitors, providing powerful tools for PDE6D biology and target validation.
- Citations
- 1
- FWCI
- 0.30
- Field percentile
- top 47%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An improved PDE6D inhibitor combines with Sildenafil to synergistically inhibit KRAS mutant cancer cell growth
P. Kaya, E. Schaffner-Reckinger, … D. K. Abankwa·bioRxiv·Aug 23, 2023
- Validation of a small molecule inhibitor of PDE6D-RAS interaction with potent anti-leukemic effects
S. C. Nunes, S. De Vita, … H. Xu·bioRxiv·Mar 14, 2022
- Computational Design of Myristoylated Cell Penetrating Peptides Targeting Oncogenic K-Ras.G12D at the Effector Binding Membrane Interface
- Identification of PDE6D as a potential target of sorafenib via PROTAC technology
- KRAS G12D can be targeted by potent salt-bridge forming inhibitors
- Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling
S. Lim, N. Boyer, … A. W. Partridge·bioRxiv·Sep 11, 2021